APIGENEX is a growing Contract Research Organization and GMP producer located in the centre of Europe (Prague, CZ). It split from the largest pharmaceutical R&D centre in former Czechoslovakia in 1999 and continues in a long tradition of pharmaceutical research.
APIGENEX has been in and benefited from the continuous and close partnership with Novo Nordisk A/S Denmark in the research of diabetes/obesity for 25 years.
APIGENEX provides high quality services in pre-clinical development and early-stage discovery in three major fields – medicinal chemistry, peptide synthesis and in-vivo/ in-vitro experimental pharmacology – to both Czech and international pharmaceutical companies.
APIGENEX has recently expanded its activities to a small-scale GMP / GLP production of highly potent API (peptides, glycopeptides).
APIGENEX has been involved in a number of research collaboration with academic institutions.
Open and interactive communication with clients is a standard together with flexibility and strict confidentiality.